Hollmén, Maija-Leena,Viitala, Miro,Jalkanen, Markku,Maksimow, Mikael
申请号：
AU2017252344
公开号：
AU2017252344A1
申请日:
2017.04.18
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
An agent capable of binding to CLEVER-1 in an individual can be used in activating macrophages to switch their phenotype from M2 macrophages into M1 macrophages. The invention relates to methods for utilizing the macrophages ability to switch their phenotype. In one aspect, the invention relates to a method for estimating of the efficacy of anti-CLEVER-1 therapy by monitoring a modulation of M2 macrophages into M1 macrophages, when an agent capable of binding to CLEVER-1 is administered in a patient, wherein an increased TNF-alpha secretion or HLA-DR expression is indicative of modulation of M2 macrophages into M1 macrophages.
